These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30673871)

  • 1. Comparative analysis of co-occurring mutations of specific tumor suppressor genes in lung adenocarcinoma between Asian and Caucasian populations.
    Zhang Y; Ma Y; Li Y; Shen X; Yu Y; Pan Y; Zhang Y; Zheng D; Zhao Y; Ye T; Li B; Hu H; Sun Y; Zhang Y; Xiang J; Chen H
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):747-757. PubMed ID: 30673871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis.
    Zhao Y; Pan Y; Cheng C; Zheng D; Zhang Y; Gao Z; Fu F; Li H; Zheng S; Zhuge L; Mao H; Kuang M; Tao X; Peng Y; Hu H; Xiang J; Li Y; Sun Y; Chen H
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1781-1789. PubMed ID: 32361787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency and clinical significance of NF1 mutation in lung adenocarcinomas from East Asian patients.
    Pan Y; Yuan C; Cheng C; Zhang Y; Ma Y; Zheng D; Zheng S; Li Y; Jin Y; Sun Y; Chen H
    Int J Cancer; 2019 Jan; 144(2):290-296. PubMed ID: 30230541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common cancer-driver mutations and their association with abnormally methylated genes in lung adenocarcinoma from never-smokers.
    Tessema M; Rossi MR; Picchi MA; Yingling CM; Lin Y; Ramalingam SS; Belinsky SA
    Lung Cancer; 2018 Sep; 123():99-106. PubMed ID: 30089603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
    Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.
    Sun Y; Ren Y; Fang Z; Li C; Fang R; Gao B; Han X; Tian W; Pao W; Chen H; Ji H
    J Clin Oncol; 2010 Oct; 28(30):4616-20. PubMed ID: 20855837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer.
    van Beek EJAH; Hernandez JM; Goldman DA; Davis JL; McLaughlin K; Ripley RT; Kim TS; Tang LH; Hechtman JF; Zheng J; Capanu M; Schultz N; Hyman DM; Ladanyi M; Berger MF; Solit DB; Janjigian YY; Strong VE
    Ann Surg Oncol; 2018 Jul; 25(7):2027-2033. PubMed ID: 29725898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population effect model identifies gene expression predictors of survival outcomes in lung adenocarcinoma for both Caucasian and Asian patients.
    Cai G; Xiao F; Cheng C; Li Y; Amos CI; Whitfield ML
    PLoS One; 2017; 12(4):e0175850. PubMed ID: 28426704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruptive and Truncating TP53 Mutations Are Associated with African-Ancestry and Worse Prognosis in Brazilian Patients with Lung Adenocarcinoma.
    Cavagna RO; Pinto IA; Escremim de Paula F; Berardinelli GN; Sant'Anna D; Santana I; da Silva VD; Da Silva ECA; Miziara JE; Mourão Dias J; Antoniazzi A; Jacinto A; De Marchi P; Molina-Vila MA; Ferro Leal L; Reis RM
    Pathobiology; 2023; 90(5):344-355. PubMed ID: 37031678
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Biton J; Mansuet-Lupo A; Pécuchet N; Alifano M; Ouakrim H; Arrondeau J; Boudou-Rouquette P; Goldwasser F; Leroy K; Goc J; Wislez M; Germain C; Laurent-Puig P; Dieu-Nosjean MC; Cremer I; Herbst R; Blons H; Damotte D
    Clin Cancer Res; 2018 Nov; 24(22):5710-5723. PubMed ID: 29764856
    [No Abstract]   [Full Text] [Related]  

  • 11. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
    La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
    Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.
    Ma Z; Zhang Y; Deng C; Fu F; Deng L; Li Y; Chen H
    J Thorac Cardiovasc Surg; 2022 Jan; 163(1):e73-e85. PubMed ID: 32739163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.
    Li C; Fang R; Sun Y; Han X; Li F; Gao B; Iafrate AJ; Liu XY; Pao W; Chen H; Ji H
    PLoS One; 2011; 6(11):e28204. PubMed ID: 22140546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations.
    Leal LF; de Paula FE; De Marchi P; de Souza Viana L; Pinto GDJ; Carlos CD; Berardinelli GN; Miziara JE; da Silva CM; Silva ECA; Pereira R; de Oliveira MA; Scapulatempo-Neto C; Reis RM
    Sci Rep; 2019 Mar; 9(1):3209. PubMed ID: 30824880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
    West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma.
    Liu DH; Zhao ZR; Lin YB; Zhou WJ; Hou JY; Ye ZH; Long H
    Ann Surg Oncol; 2019 Jun; 26(6):1934-1941. PubMed ID: 30820786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies.
    Qian J; Nie W; Lu J; Zhang L; Zhang Y; Zhang B; Wang S; Hu M; Xu J; Lou Y; Dong Y; Niu Y; Yan B; Zhong R; Zhang W; Chu T; Zhong H; Han B
    Int J Cancer; 2020 Jun; 146(11):3124-3133. PubMed ID: 31583695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
    Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN.
    Regina S; Valentin JB; Lachot S; Lemarié E; Rollin J; Gruel Y
    Clin Chem; 2009 Oct; 55(10):1834-42. PubMed ID: 19661141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
    Gow CH; Hsieh MS; Wu SG; Shih JY
    Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.